AMGN and KYKOY Related Headlines
Go Back- Amgen and Kyowa Kirin report one-year rocatinlimab safety data
- AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

